Inavolisib (GDC-0077) is a novel PI3Kα inhibitor [183] and offers high selectivity and specificity, effectively inhibiting tumor growth driven by PIK3CA mutations while minimizing the inhibition of wild-type PI3K, thereby reducing side effects. The gene discussed is PIK3CA; the disease is neoplasm.